Search Patents
  • LICHENASE-COVID-19 BASED VACCINE
    Publication number: 20210283243
    Abstract: The present invention includes an immunogenic protein, nucleic acid, plant and immunization comprising a fusion protein that has at least 90% amino acid identity to an amino acid sequence of a modified thermostable lichenase (LicKM) polypeptide as set forth in SEQ ID NO:9, wherein the LicKM polypeptide comprises an N-terminus, a C-terminus, and an inner loop region, and wherein a Receptor Binding Domain (RBD) or a Receptor Binding Motif (RBM) of a coronavirus spike protein is positioned at, at least one of, the N-terminus, the C-terminus, or in a loop region of the LicKM polypeptide.
    Type: Application
    Filed: March 11, 2021
    Publication date: September 16, 2021
    Inventor: Sylvain Marcel
  • USE OF TRANSFERRIN, TRANSFERRIN RECEPTOR AND ANTIBODY THEREOF IN PREPARATION OF ANTI-SARS-CoV-2 DRUG
    Publication number: 20230060040
    Abstract: The present disclosure provides use of transferrin, a transferrin receptor and an antibody thereof in the preparation of an anti-SARS-CoV-2 drug. Use of the transferrin, the transferrin receptor or the transferrin receptor antibody in the preparation of an anti-SARS-CoV-2 drug is provided. Both surface plasmon resonance (SPR) and immunofluorescence confirm that the SARS-CoV-2 binds to the transferrin receptor through SARS-CoV-2 spike protein; the transferrin and/or the transferrin receptor antibody competitively bind(s) to the transferrin receptor of the body, or the transferrin receptor competitively binds to a site of the SARS-CoV-2 to inhibit binding of the SARS-CoV-2 to the transferrin receptor of the body; thus, the opportunity that the SARS-CoV-2 infects cells is blocked, and the antiviral effect of the body is realized.
    Type: Application
    Filed: June 29, 2020
    Publication date: February 23, 2023
    Inventors: Ren LAI, Xiaozhong PENG, Xiaopeng TANG, Zhiyi LIAO, Shuaiyao LU, Hongqi LIU
  • VACCINE COMPOSITION FOR PREVENTING OR TREATING INFECTION OF SARS-COV-2
    Publication number: 20230257425
    Abstract: Provided is a recombinant protein for preventing or treating infection of SARS-Coronavirus-2 antigen comprising an extended receptor binding domain (RBD) of a spike protein of SARS-Coronavirus-2, and a vaccine composition comprising thereof. Also the present invention relates to a method for preventing infection of SARS-Coronavirus-2 by administering the recombinant antigen protein to a subject. The present invention can prevent COVID-19 infection. The present invention can be used as a vaccine.
    Type: Application
    Filed: April 29, 2021
    Publication date: August 17, 2023
    Inventors: Teawoo KWON, YoonJae LEE, Eun-som KIM, Seung-hye HONG, Ki-weon SEO, Sujeen LEE
  • Diagnostics for sars virus
    Publication number: 20070092938
    Abstract: This invention relates to Severe Acute Respiratory Syndrome associated coronavirus (SARS virus) isolated and recombinant proteins, in particular the nucleocapsid (N) protein and spike (S) protein, as well as fragments thereof and their use in the diagnosis, treatment and prevention of Severe Acute Respiratory Syndrome (SARS). The proteins and fragments carry epitopes that are specific for the SARS virus. Thus, detection methods based on these proteins or fragments as well as the monoclonal antibodies against these proteins or fragments are specific for the SARS virus.
    Type: Application
    Filed: February 4, 2004
    Publication date: April 26, 2007
    Applicant: Temasek Life Sciences Laboratory
    Inventors: Jimmy Kwang, Ai Ling, Eng Ooi, Hiok Chng
  • COMPOSITIONS INCORPORATING SULFATED POLYSACCHARIDES FOR INHIBITING SARS-COV-2
    Publication number: 20230201249
    Abstract: The composition inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via competitive binding to SARS-CoV-2 spike protein. The composition includes a plurality of sulfated glycosaminoglycans which bind to SARS-CoV-2 spike protein, preventing binding to and uptake by host cells. The sulfated glycosaminoglycans, including N-, 2-O, 3-O, or 6-O sulfate groups, or combinations thereof, include heparins and fucoidans, such as those isolated from brown seaweed. The compositions show antiviral activity, with EC50 as low as 0.08 ?M, and low cytotoxicity, making it promising for clinical use. While established SARS-CoV-2 treatments such as remdesivir need to be administered intravenously, the compositions discussed herein are advantageously capable to being delivered as a nasal spray, metered dose inhaler, oral delivery, etc.
    Type: Application
    Filed: April 2, 2021
    Publication date: June 29, 2023
    Inventors: Robert John LINHARDT, So-Young KIM, Weihua JIN, Jonathan Seth DORDICK, Fuming ZHANG, Seok-Joon KWON, Paul S. KWON, Keith FRASER
  • Inactivation of Genome Enveloped within Coronavirus Spherical or Pleomorphic Particles or Shells to Form a Vaccine
    Publication number: 20230226172
    Abstract: Vaccine based on ethanol inactivated pathogens, or part thereof, are described herein. Also disclosed are certain vaccines for treating COVID-19 or other coronavirus related diseases is created by deactivating the genome, genetic material or RNA encapsulated within the shell of virus without eliminating the spikes or spike protein, which both attaches the virus to a host cell and is detected by the body to produce antibodies. Treatment of an active coronavirus with a material such as an effective amount of ethanol will both penetrate the shell and deactivate the genetic material which causes the disease, for preparation of a vaccine.
    Type: Application
    Filed: June 11, 2021
    Publication date: July 20, 2023
    Inventors: Schossau M. Tom, Kurup K. Shree, Schossau Jorden
  • VACCINE COMPOSITIONS FOR THE TREATMENT OF CORONAVIRUS
    Publication number: 20210353741
    Abstract: The present disclosure provides compositions and methods useful for preventing and/or treating coronavirus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more coronavirus epitopes, such as, for example, from SARS-Cov-2 spike protein.
    Type: Application
    Filed: March 30, 2021
    Publication date: November 18, 2021
    Inventors: David Evander Anderson, Anne-Catherine Fluckiger
  • HIGH PHASE-PURITY GROWTH OF 1T'-TRANSITION METAL DICHALCOGENIDE MONOLAYERS
    Publication number: 20240043694
    Abstract: A method of forming a 1T?-phase transition metal dichalcogenide monolayer. A transition metal precursor and a first solvent are mixed to form a first mixture. A non-oxygen chalcogen or non-oxygen chalcogen precursor and a second solvent are mixed to form a second mixture. The first mixture is rapidly injected into the second mixture at a temperature between approximately 250 and 350° C. to form a third mixture. 1T?-transition metal dichalcogenide monolayers are recovered from the third mixture. The transition metals may be molybdenum or tungsten, while the non-oxygen chalcogens may be sulfur, selenium, or tellurium. The 1T?-transition metal dichalcogenide monolayers can be grown on a variety of metal substrates to form metal@ 1T?-transition metal dichalcogenide monolayer heterostructures. A flexible 4H-Au@1T?-WS2/SiO2/PDMS SERS tape was fabricated to detect the SARS-CoV-2 spike protein. The tape is capable of attomole-level detection of SARS-CoV-2 spike protein, for real-time monitoring of COVID-19.
    Type: Application
    Filed: July 25, 2023
    Publication date: February 8, 2024
    Inventors: Hua ZHANG, Zijian LI, Li ZHAI
  • ATTENUATED POXVIRUS VECTOR BASED VACCINE FOR PROTECTION AGAINST COVID-19
    Publication number: 20230381297
    Abstract: The present invention relates to a composition for raising an immune response in an animal which prevents or decreases the risk of a coronavirus infection and decreases severity of disease. In particular, the invention relates to vaccines and/or immunogenic compositions for raising an immune response in an animal which prevents or decreases the risk of the SARS-CoV-2 disease named COVID-19 by the World Health Organization. The composition comprises an attenuated poxvirus, and especially a vaccinia virus, wherein the attenuated poxvirus genome comprises a coronavirus SARS-CoV-2 nucleic acid sequence encoding the spike protein polypeptide and or the membrane protein polypeptide and or nucleocapsid protein polypeptide and or envelope protein polypeptide or an immunogenic or functional part of any of these.
    Type: Application
    Filed: May 15, 2023
    Publication date: November 30, 2023
    Inventors: Natalie PROW, Paul Howley, Tamara Cooper, John D. Hayball, Kerrilyn R. Diener, Liang Liu, Preethi Eldi
  • VACCINE COMPOSITIONS FOR THE TREATMENT OF CORONAVIRUS
    Publication number: 20220233682
    Abstract: The present disclosure provides compositions and methods useful for preventing and/or treating coronavirus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include a spike protein from the Beta variant of SARS-Cov-2.
    Type: Application
    Filed: January 12, 2022
    Publication date: July 28, 2022
    Inventors: David Evander Anderson, Anne-Catherine Fluckiger
  • ATTENUATED POXVIRUS VECTOR BASED VACCINE FOR PROTECTION AGAINST COVID-19
    Publication number: 20210299245
    Abstract: The present invention relates to a composition for raising an immune response in an animal which prevents or decreases the risk of a coronavirus infection and decreases severity of disease. In particular, the invention relates to vaccines and/or immunogenic compositions for raising an immune response in an animal which prevents or decreases the risk of the SARS-CoV-2 disease named COVID-19 by the World Health Organization. The composition comprises an attenuated poxvirus, and especially a vaccinia virus, wherein the attenuated poxvirus genome comprises a coronavirus SARS-CoV-2 nucleic acid sequence encoding the spike protein polypeptide and or the membrane protein polypeptide and or nucleocapsid protein polypeptide and or envelope protein polypeptide or an immunogenic or functional part of any of these.
    Type: Application
    Filed: March 25, 2021
    Publication date: September 30, 2021
    Inventors: Natalie PROW, Paul Howley, Tamara Cooper, John D. Hayball, Kerrilyn R. Diener, Liang Liu, Preethi Eldi
  • Lateral Flow Device for Detection of Neutralizing Antibodies Against SARS-COV-2
    Publication number: 20230168245
    Abstract: The present disclosure provides a lateral flow device, and methods of use of the device, for accurately and rapidly detecting a COVID-19 infection in a subject. The lateral flow device described herein detects in a liquid sample from the subject the presence or absence of neutralizing and non-neutralizing anti-S1 spike antibodies as IgM and IgG types. The anti-S1 antibodies neutralizing antibodies (e.g., both IgM and IgG) can block binding between ACE2 antigen and S1 spike protein which is the basis for the design of the lateral flow device.
    Type: Application
    Filed: April 23, 2021
    Publication date: June 1, 2023
    Applicant: Sorrento Therapeutics, Inc.
    Inventor: Henry Hongjun Ji
  • SINGLE DOMAIN ANTIBODIES THAT TARGET SARS-COV-2
    Publication number: 20230374116
    Abstract: The present invention relates to improved single domain antibodies that target SARS-CoV-2, multivalent polypeptides and fusion proteins comprising the single domain antibodies. The present invention also provides coronavirus binding molecules that bind two different epitopes on the receptor binding domain of a spike protein of a coronavirus. The coronavirus binding molecules are based on joining two antigen binding molecules together via a linker. The present invention provides the use of said single domain antibodies, multivalent polypeptides, fusion proteins and coronavirus binding molecules in treating and/or preventing coronavirus, as well as the use of said single domain antibodies, multivalent polypeptides, fusion proteins and coronavirus binding molecules in the detection and diagnosis of coronavirus using various methods, assays and kits.
    Type: Application
    Filed: September 14, 2021
    Publication date: November 23, 2023
    Inventors: Jiandong Huo, Raymond Owens, James Naismith
  • COMPOSITIONS AND METHODS FOR DIAGNOSING SARS-COV-2 (COVID-19) AND FOR MONITORING SARS-COV-2-SPECIFIC IMMUNOLOGICAL MEMORY
    Publication number: 20240027450
    Abstract: Compositions and methods are provided for detection, diagnosis and prognosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) and for characterization of SARS-CoV-2 antigen-specific T-cell immune responsiveness in COVID-19 patient samples, including in secondary in vitro immune response assays for long-lived anamnestic (memory) T-cell responses. Disclosed compositions and methods include a method that comprises contacting, in vitro, whole blood samples from subjects suspected of having COVID-19 or who have previously been exposed to SARS-CoV-2, with synthetic peptides comprising T-cell epitope-containing regions derived from SARS-CoV-2 Spike proteins; and indirectly detecting SARS-CoV-2-specific activated T-cells by determining production of a T-cell immune response indicator (e.g., interferon-?) in response to stimulation by the Spike protein-derived peptides.
    Type: Application
    Filed: December 3, 2021
    Publication date: January 25, 2024
    Inventors: Jeff BOYLE, Jenny HOWARD, Soumya JAGANATHAN, Dave LEWINSOHN, Deborah LEWINSOHN, Gwendolyn SWARBRICK
  • METHODS AND COMPOSITIONS FOR DETECTING AND PRODUCING PORCINE MORBILLIVIRUS AND VACCINES THEREOF
    Publication number: 20240139306
    Abstract: Disclosed herein are methods for detecting and producing PoMV. Further, disclosed herein are immunogenic and/or vaccine compositions and methods for treating or preventing PoMV. The compositions and methods include immunogenic portions of PoMV including entry proteins. In at least particular cases, a mutated version of a portion of the PoMV is utilized, such as a deglycosylated, or amino acid substituted mutant of the spike protein.
    Type: Application
    Filed: March 1, 2022
    Publication date: May 2, 2024
    Inventors: Ganwu Li, Bailey Arruda, Huigang Shen, Ying Zheng
  • COVID-19 VACCINE
    Publication number: 20210300970
    Abstract: Provided herein are antigenic peptides comprising the SARS-CoV-2 spike protein receptor binding domain (CRBD) polypeptide or portions thereof, linked to a non-catalytic, non-toxic tetanus toxin variant (i.e., a modified tetanus toxin or “MTT”) and vaccine compositions comprising the same. In addition, provided herein are methods for making and using CRBD-MTT fusion proteins as immunogenic agents.
    Type: Application
    Filed: March 24, 2021
    Publication date: September 30, 2021
    Inventors: Joseph T. Barbieri, Amanda Przedpelski, Eric A. Johnson, Sabine Pellett, William H. Tepp
  • COMPOSITIONS FOR PREVENTING OR TREATING VIRAL AND OTHER MICROBIAL INFECTIONS
    Publication number: 20220119501
    Abstract: The present application relates to compositions for preventing or treating viral and other microbial infections. In some embodiments, the present application provides chimeric proteins comprising a target-binding moiety that specifically binds to a pathogen that infects through a mucosa, and a positively charged mucoadhesive peptide fragment. Also provided are antibodies and constructs thereof that specifically binds to an S1 subunit of a spike protein of SARS-CoV-2. Compositions comprising the chimeric proteins, antibodies, or constructs described herein are useful for preventing or treating a microbial infection in an individual, such as a coronavirus infection.
    Type: Application
    Filed: October 14, 2021
    Publication date: April 21, 2022
    Inventors: Cheng LIU, Hongbing ZHANG, Zhiyuan YANG, Jingyi XIANG, Ziyou CUI, Jianying LIU
  • COMPOSITIONS FOR PREVENTING OR TREATING VIRAL AND OTHER MICROBIAL INFECTIONS
    Publication number: 20230141962
    Abstract: The present application relates to compositions for preventing or treating viral and other microbial infections. In some embodiments, the present application provides chimeric proteins comprising a target-binding moiety that specifically binds to a pathogen that infects through a mucosa, and a positively charged mucoadhesive peptide fragment. Also provided are antibodies and constructs thereof that specifically binds to an S1 subunit of a spike protein of SARS-CoV-2. Compositions comprising the chimeric proteins, antibodies, or constructs described herein are useful for preventing or treating a microbial infection in an individual, such as a coronavirus infection.
    Type: Application
    Filed: August 4, 2022
    Publication date: May 11, 2023
    Inventors: Cheng LIU, Hongbing Zhang, Zhiyuan Yang, Jingyi Xiang, Ziyou Cui, Jianying Liu
  • Vaccine compositions for the treatment of coronavirus
    Patent number: 11253587
    Abstract: The present disclosure provides compositions and methods useful for preventing and/or treating coronavirus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more coronavirus epitopes, such as, for example, from SARS-Cov-2 spike protein.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: February 22, 2022
    Assignee: Variation Biotechnologies Inc.
    Inventors: David Evander Anderson, Anne-Catherine Fluckiger
  • SINGLE-DOMAIN ANTIBODIES THAT BIND SARS-COV-2
    Publication number: 20230331824
    Abstract: Single-domain antibodies that bind the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) spike protein are disclosed. The single-domain antibodies include binding domains that bind epitopes of the Spike ectodomain inside and outside the receptor binding domain. The single-domain antibodies can be used for multiple purposes including in the research, diagnosis, and prophylactic or therapeutic treatment of COVID-19.
    Type: Application
    Filed: August 20, 2021
    Publication date: October 19, 2023
    Applicants: The Rockefeller University, Seattle Children's Hospital d/b/a Seattle Children's Research Institute, New York University
    Inventors: Brian T. Chait, Michael P. Rout, John Aitchison, Fred David Mast, Jean Paul Olivier, David Fenyo
Narrow Results

Filter by US Classification